GRI Bio, led by CEO Marc Hertz, announced its development of modulators targeting Natural Killer T cells and presented at H.C. Wainwright.
6 reports, 2 independent
Updated Mon 00:00
No new developments lately
- Reports
- 6
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GRI Bio, led by CEO Marc Hertz, announced its development of modulators targeting Natural Killer T cells and presented at H.C. Wainwright.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Vipin Kumar joins GRI Bio as CSO; Marc Hertz remains CEO.1 source
GRI Bio CEO Marc Hertz announced NKT cell modulator development and presented at H.C. Wainwright.1 source
- GRI Bio, led by Marc Hertz, is investigating iNKT cell activation as a secondary goal in its NK T cell modulator development.
Keep exploring
The entities involved
-
Marc Hertz
American screenwriter
Nothing else this week.
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireGRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference Live webcast presentation with CEO, Dr. Marc Hertz, on September 9th at 3:00 PM ET LA JOLLA, CA, Sept. 03, 2025 (GLO
- GlobeNewswireGRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment Access the “What This Means” segment here LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GR
- GlobeNewswireGRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference – Video webcast now available on-demand LA JOLLA, CA, July 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio,
- Unknown outlet
- Unknown outlet